Skip to content

Nuvalent, Inc. NUVL Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$971K+341%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$3.8M+88.1%
Exelixis logo
ExelixisEXEL
$7.47M-35.7%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$12.21M+1,270%
Incyte logo
IncyteINCY
$97.93M+2,923%
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s stock issuance proceeds?
Nuvalent, Inc. (NUVL) reported stock issuance proceeds of $10.14M in Q1 2026.
How has Nuvalent, Inc.'s stock issuance proceeds changed year-over-year?
Nuvalent, Inc.'s stock issuance proceeds increased by 122.6% year-over-year, from $4.55M to $10.14M.
What is the long-term trend for Nuvalent, Inc.'s stock issuance proceeds?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s stock issuance proceeds has grown at a 30.6% compound annual growth rate (CAGR), from $177.27M to $515.72M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.